Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Two Treatments, Single Dose, Cross Over, Bioequivalence Study of Valsatril Tablet of SAMI Pharmaceuticals Pvt. Ltd. Versus Entresto® Tablet of Novartis Pharmaceuticals Ltd., Under Fasting Condition in Adult Healthy Subjects.

NCT07746908 is registered in ClinicalTrials.gov with Center for Bioequivalence Studies and Clinical Research as lead sponsor.

NCT NCT07746908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07746908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Two Treatments, Single Dose, Cross Over, Bioequivalence Study of Valsatril Tablet of SAMI Pharmaceuticals Pvt. Ltd. Versus Entresto® Tablet of Novartis Pharmaceuticals Ltd., Under Fasting Condition in Adult Healthy Subjects.
Lead sponsor
Center for Bioequivalence Studies and Clinical Research
Phase
Phase 1
Overall status
Completed
Start date
February 6, 2025
Completion date
July 18, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants